BioInvent International AB (BINV) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

134.19 k

Shareholding (Dec 2015)

FII

0.91%

Held by 1 FIIs

DII

99.09%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate -181.56% of over the last 5 years

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 2,053 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-47.43%

Price to Book

3.01

Revenue and Profits:

Net Sales:

198 Million

(Quarterly Results - Jun 2025)

Net Profit:

39 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-2.68%

6 Months

-24.94%

1 Year

-33.83%

2 Years

88.88%

3 Years

-19.75%

4 Years

-36.21%

5 Years

-34.72%

BioInvent International AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

27.03%

EBIT Growth (5y)

-181.56%

EBIT to Interest (avg)

-263.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.95

Sales to Capital Employed (avg)

0.11

Tax Ratio

0.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.91%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.30

EV to EBIT

-3.35

EV to EBITDA

-3.57

EV to Capital Employed

48.19

EV to Sales

4.24

PEG Ratio

Dividend Yield

ROCE (Latest)

-1437.52%

ROE (Latest)

-36.01%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2015

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.91%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 796.38% vs 3.27% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 133.28% vs 0.26% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "198.10",
          "val2": "22.10",
          "chgp": "796.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "40.10",
          "val2": "-118.10",
          "chgp": "133.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "38.80",
          "val2": "-116.60",
          "chgp": "133.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "176.90%",
          "val2": "-5,585.80%",
          "chgp": "576.27%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -37.48% vs -78.07% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -30.00% vs -677.18% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44.70",
          "val2": "71.50",
          "chgp": "-37.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-452.00",
          "val2": "-353.80",
          "chgp": "-27.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-429.40",
          "val2": "-330.30",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,548.00%",
          "val2": "-5,185.80%",
          "chgp": "-536.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

198.10

22.10

796.38%

Operating Profit (PBDIT) excl Other Income

40.10

-118.10

133.95%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

38.80

-116.60

133.28%

Operating Profit Margin (Excl OI)

176.90%

-5,585.80%

576.27%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 796.38% vs 3.27% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 133.28% vs 0.26% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

44.70

71.50

-37.48%

Operating Profit (PBDIT) excl Other Income

-452.00

-353.80

-27.76%

Interest

0.60

Exceptional Items

0.00

Consolidate Net Profit

-429.40

-330.30

-30.00%

Operating Profit Margin (Excl OI)

-10,548.00%

-5,185.80%

-536.22%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -37.48% vs -78.07% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -30.00% vs -677.18% in Dec 2023

All Annual Results

Company CV

About BioInvent International AB

BioInvent International AB

Pharmaceuticals & Biotechnology

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Company Coordinates

Company Details

Ideon Science Park , LUND None : 223 70

Tel: 46 46 286855046 46 2868550

http://www.bioinvent.se/

Registrar Details